feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Calliditas Therapeutics: Our Comment on Phase I Data with Setanaxib
Research Note
2021-01-19
07:20
Redeye gives a brief comment on the phase I results with setanaxib announced yesterday.
LS
Ludvig Svensson
Sign up for free to continue
Sign up with Email
Sign in with Google
Already a member?
Sign in
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans